RT Journal Article
SR Electronic
T1 From multiplex serology to serolomics – a novel approach to the antibody response against the SARS-CoV-2 proteome
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.19.20214916
DO 10.1101/2020.10.19.20214916
A1 Butt, Julia
A1 Murugan, Rajagopal
A1 Hippchen, Theresa
A1 Olberg, Sylvia
A1 van Straaten, Monique
A1 Wardemann, Hedda
A1 Stebbins, Erec
A1 Kräusslich, Hans-Georg
A1 Bartenschlager, Ralf
A1 Brenner, Hermann
A1 Laketa, Vibor
A1 Schöttker, Ben
A1 Müller, Barbara
A1 Merle, Uta
A1 Waterboer, Tim
YR 2020
UL http://medrxiv.org/content/early/2020/10/21/2020.10.19.20214916.abstract
AB Background The emerging SARS-CoV-2 pandemic entails an urgent need for specific and sensitive high-throughput serological assays to assess SARS-CoV-2 epidemiology. We therefore aimed at developing a fluorescent-bead based SARS-CoV-2 multiplex serology assay for detection of antibody responses to the SARS-CoV-2 proteome.Methods Proteins of the SARS-CoV-2 proteome and protein N of SARS-CoV-1 and common cold Coronaviruses (ccCoVs) were recombinantly expressed in E. coli or HEK293 cells. Assay performance was assessed in a Covid-19 case cohort (n=48 hospitalized patients from Heidelberg) as well as n=85 age- and sex-matched pre-pandemic controls from the ESTHER study. Assay validation included comparison with home-made immunofluorescence and commercial Enzyme-linked immunosorbent (ELISA) assays.Results A sensitivity of 100% (95% CI: 86%-100%) was achieved in Covid-19 patients 14 days post symptom onset with dual sero-positivity to SARS-CoV-2 N and the receptor-binding domain of the spike protein. The specificity obtained with this algorithm was 100% (95% CI: 96%-100%). Antibody responses to ccCoVs N were abundantly high and did not correlate with those to SARS-CoV-2 N. Inclusion of additional SARS-CoV-2 proteins as well as separate assessment of immunoglobulin (Ig) classes M, A, and G allowed for explorative analyses regarding disease progression and course of antibody response.Conclusion This newly developed SARS-CoV-2 multiplex serology assay achieved high sensitivity and specificity to determine SARS-CoV-2 sero-positivity. Its high throughput ability allows epidemiologic SARS-CoV-2 research in large population-based studies. Inclusion of additional pathogens into the panel as well as separate assessment of Ig isotypes will furthermore allow addressing research questions beyond SARS-CoV-2 sero-prevalence.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was generously supported by the Dieter Morszeck Stiftung. Data and sample collection for the ESTHER study were supported by a grant from the Baden-Wuerttemberg State Ministry of Science, Research and Arts.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committee of the Medical Faculty Heidelberg (approval number S-148/2020) and conducted in accordance with the Declaration of Helsinki. The ESTHER study was approved by the ethics committees of the University of Heidelberg (approval number S-058/2000) and the medical board of the state of Saarland (approval number 67/00). Written informed consent was obtained from each participant.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll summary data generated or analyzed during this study are included in this published article and its supplementary material file. The primary data are available from the corresponding author on reasonable request.